They found that rapamycin, especially when administered with a Beclin-1 plasmid transfection group, demonstrated an increase of the pro-apoptotic factor Bax and low levels of the anti-apoptotic Bcl-2, thus decreasing the viability of tumor cells and promoting apoptosis. Here, BCL2 is linked to neoplasm.